usually Emicizumab-kxwh Pronunciation (em i SIZ ue mab kxwh) Index Terms Hemlibra Pharmacologic Category Antihemophilic Agent Monoclonal Antibody Use: Labeled Indications Routine prophylaxis of bleeding events in patients with hemophilia: Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors Contraindications There are no contraindications listed in the manufacturer's labeling. Adverse Reactions >10%: Central nervous system: Headache (15%) Immunologic: Antibody development ( 22%) Local: Injection site reaction (19%) 1% to 10%: Dermatologic: Injection site pruritus (5%) Gastrointestinal: Diarrhea (6%) Local: Erythema at injection site (7%), pain at injection site (5%) Neuromuscular & skeletal: Arthralgia (10%), myalgia (5%) Miscellaneous: Fever (7%) ALERT: U.S. Boxed Warning Thrombotic microangiopathy and thromboembolism: Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 units/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving emicizumab-kxwh prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of emicizumab-kxwh if symptoms occur. Print this page Recently Approved Lonhala Magnair Lonhala Magnair (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator for... Ozempic Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the... Ogivri Ogivri (trastuzumab-dkst) is a HER2 / neu receptor antagonist biosimilar to Herceptin indicated for... Sublocade Sublocade (buprenorphine) is a once-monthly injectable partial opioid agonist formulation for the... More the infant
abruptly Emicizumab-kxwh try to
EmoticonEmoticon